Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mibefradil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H known ✓ | O95180 | 10/20 | 0.99 |
| ▸ | CACNA1G known ✓ | O43497 | 1/20 | 0.99 |
| ▸ | CACNA1I known ✓ | Q9P0X4 | 1/20 | 0.99 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 8/20 | 0.99 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.99 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.99 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.99 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.99 |
| ▸ | NPC1 | O15118 | 1/20 | 0.99 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.99 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mibefradil SCHEMBL29412446 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ANPSR1ABCB11 | |
| Mibefradil SCHEMBL7400127 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ANPSR1ABCB11 | |
| Mibefradil SCHEMBL908985 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ANPSR1ABCB11 | |
| Mibefradil SCHEMBL5500513 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ANPSR1ABCB11 | |
| Mibefradil SCHEMBL18210637 | 0.99 | NPSR1 (1.00) | MAPTMEN1KMT2ANPSR1ABCB11 | |
| Mibefradil SCHEMBL2230258 | 0.99 | CACNA1H (1.00) | MAPTMEN1KMT2ANPSR1ABCB11 | |
| Mibefradil SCHEMBL7708100 | 0.99 | CACNA1H (1.00) | MAPTMEN1KMT2ANPSR1ABCB11 | |
| Mibefradil SCHEMBL29359482 | 0.99 | CACNA1H (1.00) | MAPTMEN1KMT2ANPSR1ABCB11 | |
| Mibefradil SCHEMBL22968530 | 0.99 | CACNA1H (1.00) | MAPTMEN1KMT2ANPSR1ABCB11 | |
| Mibefradil SCHEMBL7265837 | 0.99 | CACNA1H (1.00) | MAPTMEN1KMT2ANPSR1ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 625 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| US-20230346879-A1 | COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2023-11-02 | — | — | US | claimed |
| EP-3810184-A2 | METHODS OF TREATING OR INHIBITING ONSET OF HUNTINGTON'S DISEASE | University of Rochester (US) | 2021-04-28 | — | — | EP | claimed |
| CN-112654366-A | Methods of treating or inhibiting the onset of huntington's disease | 罗切斯特大学 | 2021-04-13 | — | — | CN | claimed |
| US-20200353033-A1 | COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS | THE BROAD INSTITUTE, INC. (US) | 2020-11-12 | — | — | US | claimed |
| US-20200262877-A1 | ION CHANNEL-BINDING PEPTIDES AND METHODS OF USE THEREOF | BLAZE BIOSCIENCE INC (US) | 2020-08-20 | — | — | US | claimed |
| WO-2019074858-A1 | ION CHANNEL-BINDING PEPTIDES AND METHODS OF USE THEREOF | Blaze Bioscience, Inc. (US) | 2019-04-18 | — | — | WO | claimed |
| WO-2017161387-A1 | COMPOSITIONS OF NATURAL EXTRACTS AND USE THEREOF IN METHODS FOR PREVENTING OR TREATING DISEASES | REID CHRISTOPHER BRIAN (US) | 2017-09-21 | — | — | WO | claimed |
| US-20140271923-A1 | Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions | REID CHRISTOPHER BRIAN (US) | 2014-09-18 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-6472425-B1 | Methods for treating female sexual dysfunctions | NITROMED, INC. | 2002-10-29 | — | — | US | claimed |
| US-6462044-B2 | THERAPY FOR SEXUAL DISORDERS | NITROMED, INC. | 2002-10-08 | — | — | US | claimed |
| US-6331543-B1 | TREATING SEXUAL DYSFUNCTION | NITROMED, INC. | 2001-12-18 | — | — | US | claimed |
| US-6197778-B1 | THERAPY FOR SEXUAL DISORDERS | NITROMED, INC. | 2001-03-06 | — | — | US | claimed |
| US-12628817-B2 | Method for increasing the lifespan and motility of animal sperm using an inhibitor of Slo3 potassium channel | IMV TECHNOLOGIES (FR) | 2026-05-19 | — | — | US | disclosed |
| US-4808605-A | Tetrahydronaphthalene derivatives as calcium antagonists | HOFFMANN-LA ROCHE INC. (US) | 1989-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346879-A1 | COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS | RAB5IF, CLTB, TBK1 | CACNA1H 4747/4885CACNA1G 4757/4885CACNA1I 4669/4885 |
| US-12628817-B2 | Method for increasing the lifespan and motility of animal sperm using an inhibitor of Slo3 potassium channel | CATSPER1, KCNN3, KCNA3 | CACNA1H 156/4885CACNA1G 109/4885CACNA1I 71/4885 |
| US-20200353033-A1 | COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS | RAB5IF, CLTB, TBK1 | CACNA1H 4747/4885CACNA1G 4757/4885CACNA1I 4669/4885 |
| US-20200262877-A1 | ION CHANNEL-BINDING PEPTIDES AND METHODS OF USE THEREOF | TRPV1, SCNN1G, CACNB2 | CACNA1H 77/4885CACNA1G 41/4885CACNA1I 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.